Research programme: eye and ear disorder therapies - HanAll Biopharma
Latest Information Update: 08 Jun 2024
At a glance
- Originator HanAll Biopharma
- Class Eye disorder therapies; RNA
- Mechanism of Action Gene expression regulation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ear disorders; Eye disorders